Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

Nutritional approaches to prevention and treatment of gallstones.

Gaby AR.

Altern Med Rev. 2009 Sep;14(3):258-67. Review.

2.

[Innovations in the medical treatment of gallstones and fatty liver: FABACs (Fatty Acid Bile Acid Conjugates)].

Keizman D, Goldiner I, Leikin-Frenkel A, Konikoff FM.

Harefuah. 2008 Apr;147(4):344-9, 373, 372. Review. Hebrew.

PMID:
18686819
3.
4.

Effect of the type of dietary fat on biliary lipid composition and bile lithogenicity in humans with cholesterol gallstone disease.

Yago MD, González V, Serrano P, Calpena R, Martínez MA, Martínez-Victoria E, Mañas M.

Nutrition. 2005 Mar;21(3):339-47.

PMID:
15797676
5.

[Internist therapy of cholelithiasis].

Riemann JF.

Fortschr Med. 1981 May 28;99(20):755-60. German.

PMID:
7262755
6.

Ascorbic acid and cholesterol gallstones.

Simon JA.

Med Hypotheses. 1993 Feb;40(2):81-4.

PMID:
8455479
7.

Stones in the common bile duct: experience with medical dissolution therapy.

Somerville KW, Ellis WR, Whitten BH, Balfour TW, Bell GD.

Postgrad Med J. 1985 Apr;61(714):313-6.

8.

Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones.

Jüngst C, Sreejayan N, Zündt B, Müller I, Spelsberg FW, Hüttl TP, Kullak-Ublick GA, del Pozo R, Jüngst D, von Ritter C.

Eur J Clin Invest. 2008 Sep;38(9):634-9. doi: 10.1111/j.1365-2362.2008.01995.x.

PMID:
18837739
9.

Gallstones - approach to medical management.

Konikoff FM.

MedGenMed. 2003 Oct 15;5(4):8. Review.

10.

Drugs affecting biliary lipid secretion and gallbladder motility: their potential role in gallstone treatment and prevention.

vanBerge-Henegouwen GP, Venneman NG, van Erpecum KJ, Portincasa P.

Curr Drug Targets Immune Endocr Metabol Disord. 2005 Jun;5(2):185-91. Review.

PMID:
16089351
11.

Failure of cholecystokinin-octapeptide to prevent TPN-associated gallstone disease.

Tsai S, Strouse PJ, Drongowski RA, Islam S, Teitelbaum DH.

J Pediatr Surg. 2005 Jan;40(1):263-7.

PMID:
15868595
12.

Obesity, dyslipidemia and cholesterol gallstone disease during one year of Antarctic residence.

Premkumar M, Sable T.

Rural Remote Health. 2012;12:2186. Epub 2012 Nov 17.

13.

Contributions of obesity and weight loss to gallstone disease.

Everhart JE.

Ann Intern Med. 1993 Nov 15;119(10):1029-35. Review.

PMID:
8214980
14.

The role of dietary fats in the pathogenesis of gallstones.

Méndez-Sánchez N, Chavez-Tapia NC, Uribe M.

Front Biosci. 2003 May 1;8:e420-7. Review.

PMID:
12700135
15.

[New aspects in the treatment of cholecysto-and choledolithiasis].

Preisig R, Halter F, Bircher J.

Schweiz Med Wochenschr. 1981 Feb 28;111(9):297-302. German.

PMID:
7221531
16.

[Dietetic influences on the formation and prevention of cholesterol gallstones].

Trautwein EA.

Z Ernahrungswiss. 1994 Mar;33(1):2-15. Review. German.

PMID:
8197785
17.

Gallstone disease: Primary and secondary prevention.

Venneman NG, van Erpecum KJ.

Best Pract Res Clin Gastroenterol. 2006;20(6):1063-73. Review.

PMID:
17127188
18.
19.

[Nutritional risk factors for gallstones. Epidemiological analysis].

García V, Serra I, Palma R.

Rev Med Chil. 1998 Oct;126(10):1247-54. Spanish.

PMID:
10030098
20.

Effects of fatty acid bile acid conjugates (FABACs) on biliary lithogenesis: potential consequences for non-surgical treatment of gallstones.

Konikoff FM, Gilat T.

Curr Drug Targets Immune Endocr Metabol Disord. 2005 Jun;5(2):171-5. Review.

PMID:
16089349
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk